Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval follows a positive opinion issued in September by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). “We are delighted by the European Commission’s approval of Zynlonta” said Anders Ullman, Head of Research & Development and Medical Affairs, Chief Medical Officer at Sobi.